Byondis ernennt Dr. Louis Denis to Chief Medical Officer

Byondis BV, a unique biopharmaceutical company, which employs innovative, soul-oriented medicines for credit patients, gives the experience of Dr. Louis Denis his Chief Medical Officer. Dr. Denis brought more than 30 years of experience in clinical treatment and expertise in oncology to medicine.

This press conference has provided a multimedia inhalation. The full Mitteilung can be found here: https://www.businesswire.com/news/home/20241118217981/de/

Louis Denis, MD, Chief Medical Officer, Byondis (Photo: Business Wire)

“We are friends with Louis and our Byondis-Team is the first to build on our successful company’s own business research, research and development. In any case, our internal CMC-Fähigkeiten became the basis for future research and research into the development of Krebsmedicamenten von unschätzbarem Wert sein, um unsere Pipeline will go through the clinical phase and letztendlich Patients to erreichen,” says Byondis-Gründer and CEO Dr. Jacques Lemmens.

“Byondis is a foundation fund for clearing things, a strong financing strategy and an expansion of the pipeline to new anti-law substance conjugates and anti-treatment therapies that are well positioned, one of the best treatments for lending to your credit,” said Dr. Dennis. “I am very happy, together with the last generation who care for the treatment of patients and prepare for it.”

Before Dr. Denis was Chief Medical Officer at Verastem Oncology and Asana BioSciences in 2015, he worked at Byondis. Zuvor has Dr. Denis held medical positions in clinical treatment and medical affairs at Boehringer Ingelheim and Pfizer inne. Dr. Denis obtained his PhD at the Vrije Universiteit Brussel, Belgium, and completed several Postdoc Fellowships in the field of Inner Medicine/Medizinische Onkologie at the Middelheim Hospital in Antwerp, at the Rotterdam Cancer Institute in the Netherlands and at the Institute for Drug Development, Cancer Therapy and Research Center in San Antonio, Texas.

Uber Byondis

Byondis is an unacceptable biopharmaceutical Forschungs- und Entwicklungsunternehmen, the innovative, soul-oriented medicine gets credit, a life of patients with a word. There are new biological Einheiten (NBEs) with Schwerpunkt in Antikörper-Wirkstoff-Konjugaten und antikörperbasierten Therapeutika.

The Byondis Breite Entwicklungsportfolio is an important practice and fresh clinical program. The production candidates of Byondis’ Fachwissen in de Bereichen Linker-Drug-Technologie (LD), Antikörper-Wirkstoff-Konjugatie, souled zytotoxic Therapy, Immunology and Entwicklung monoclonal Antikörper (mAb). Byondis’ expertise is based in the company’s manufacturing and development operations, with the manufacturing leadership structure clinically tasked with outsourcing product candidates, all of which will be executed in-house.

Our team develops high-tech F&E and GMP production systems in Nijmegen, the Netherlands, a team of more than 300 employees. More information can be found at www.byondis.com.

The general text, in the original text which is light, is the official and authorized version. The settings need to be adjusted. Nur de Sprachversion, de originale veröffentlichte wurde, is legalgültig. Use the original version of the view ab.

Original version on businesswire.com as follows: https://www.businesswire.com/news/home/20241118217981/de/

Contacts:

Suzanne van Gerwen

Email: [email protected]
Direct: +31246795340